Galderma Group AG's total inventories for the quarter that ended in Dec. 2025 was $525 Mil. Galderma Group AG's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was $514 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Galderma Group AG's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was $-3.01.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Galderma Group AG's Days Inventory for the
six
months ended in Dec. 2025 was 107.59.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Galderma Group AG's Inventory Turnover for the quarter that ended in Dec. 2025 was 1.70.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Galderma Group AG's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.19.
Galderma Group AG (OTCPK:GALDY) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Galderma Group AG's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Galderma Group AG's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Galderma Group AG Total Inventories Related Terms
Galderma Group AG Total Inventories Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Galderma Group AG (GALDY) has a Total Inventories of $525 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Galderma Group AG and its competitors.
Is Galderma Group AG's Total Inventories too high?
Galderma Group AG's current Total Inventories is $525 Mil. Overall, Galderma Group AG has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Total Inventories compare to ZTS and UTHR?
Galderma Group AG's Total Inventories of $525 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Galderma Group AG and its competitors. Galderma Group AG's current Total Inventories is $525 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (GALDY) has a current Total Inventories of $525 Mil. The current Total Inventories is $525 Mil. Galderma Group AG's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Galderma Group AG (GALDY), the current Total Inventories is $525 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
21GF Score
Get the complete analysis for GALDY
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GALDY has been successfully added to your 